Inhibikase Therapeutics Inc. (IKT) Social Stream



Inhibikase Therapeutics Inc. (IKT): $2.30

0.01 (+0.44%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Add IKT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#229 of 363

in industry

INHIBIKASE THERAPEUTICS INC (IKT) Price Targets From Analysts

Use the tables below to see what analysts covering INHIBIKASE THERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2023-05-16 1 $5 $5 $5 $1.39 259.71%
2023-08-15 1 $27 $27 $27 $1.39 1842.45%
NA 1 $NA $NA $NA $1.39 NA%

Price Target Last Issued NA NA, NA

The Trend in the Analyst Price Target


Over the past 27 months, IKT's average price target has gone up $12.

IKT reports an average of 1,528.15% for its upside potential over the past 119 days.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-04-18 1 5.000 5.000 5.000 0.579 763.56%
2023-05-16 1 5.000 5.000 5.000 0.651 668.05%
2023-05-16 1 29.994 29.994 29.994 0.651 4507.37%
2023-06-30 1 27.000 27.000 27.000 3.610 647.92%
2023-08-15 1 27.000 27.000 27.000 2.340 1053.85%

IKT Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 1 0 0 0 0 1

The Trend in the Broker Recommendations


Over the past 92 days, IKT's average broker recommendation rating improved by 0.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In the context of all US stocks, INHIBIKASE THERAPEUTICS INC's number of analysts covering the stock is higher than nearly none of them.
  • To contextualize these metrics, consider that out of all US stocks, INHIBIKASE THERAPEUTICS INC's variance in analysts' estimates is lower than nearly 100% of them.
  • In terms of how INHIBIKASE THERAPEUTICS INC fares relative to Healthcare stocks, note that its upside potential (average analyst target price relative to current price) is greater than 263.25% of that group.
  • In terms of how INHIBIKASE THERAPEUTICS INC fares relative to stocks in the micro market cap category, note that its average analyst price target is higher than 201.14% of that group.

In the Pharmaceutical Products industry, TCRX, PMCB, and HUGE are the three stocks most similar to INHIBIKASE THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.

Is IKT a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!